×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
NASDAQ:VECT

VectivBio Stock Forecast, Price & News

$5.96
+0.09 (+1.53%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.94
$6.01
50-Day Range
$4.20
$6.55
52-Week Range
$2.74
$11.00
Volume
7,297 shs
Average Volume
23,203 shs
Market Capitalization
$202.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

VectivBio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
286.2% Upside
$23.00 Price Target
Short Interest
Healthy
0.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of VectivBio in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.47) to ($2.48) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.87 out of 5 stars

Medical Sector

662nd out of 1,433 stocks

Biological Products, Except Diagnostic Industry

100th out of 220 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive VECT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

VECT Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
VectivBio prices $30M follow-on stock offering
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
VectivBio Announces Third Quarter 2021 Business Update
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VECT
Fax
N/A
Employees
N/A
Year Founded
N/A

Company Calendar

Today
7/07/2022
Next Earnings (Estimated)
7/07/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$23.00
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+286.2%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.41 per share

Miscellaneous

Free Float
N/A
Market Cap
$202.58 million
Optionable
Not Optionable
Beta
-0.61














VectivBio Frequently Asked Questions

Should I buy or sell VectivBio stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VectivBio stock.
View analyst ratings for VectivBio
or view top-rated stocks.

What is VectivBio's stock price forecast for 2022?

1 brokers have issued 12 month price targets for VectivBio's stock. Their VECT stock forecasts range from $23.00 to $23.00. On average, they expect VectivBio's stock price to reach $23.00 in the next year. This suggests a possible upside of 286.2% from the stock's current price.
View analysts' price targets for VectivBio
or view top-rated stocks among Wall Street analysts.

How has VectivBio's stock price performed in 2022?

VectivBio's stock was trading at $4.91 at the beginning of 2022. Since then, VECT stock has increased by 21.3% and is now trading at $5.9557.
View the best growth stocks for 2022 here
.

When is VectivBio's next earnings date?

VectivBio is scheduled to release its next quarterly earnings announcement on Thursday, July 7th 2022.
View our earnings forecast for VectivBio
.

Who are VectivBio's key executives?

VectivBio's management team includes the following people:
  • Dr. Luca Santarelli M.D., Founder, CEO & Director (Age 53)
  • Ms. Claudia D'Augusta Ph.D., Chief Financial Officer (Age 52)
  • Dr. Christian Meyer M.D., Ph.D., Chief Operating Officer (Age 55)
  • Dr. Alain Bernard Ph.D., Chief Technology Officer (Age 65)
  • Mr. Patrick Malloy, Sr. VP of Investor Relations & Strategic Communications
  • Mr. Scott Applebaum, Chief Legal Officer & Corp. Sec. (Age 55)
  • Mr. Michael Steininger, Sr. VP & Head of HR
  • Mr. Kevin Harris M.B.A., Chief Commercial Officer (Age 51)
  • Dr. Sarah Holland Ph.D., Chief Bus. Officer (Age 59)
  • Dr. Omar Khwaja M.D., Ph.D., Chief Medical Officer (Age 51)

When did VectivBio IPO?

(VECT) raised $128 million in an IPO on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

What is VectivBio's stock symbol?

VectivBio trades on the NASDAQ under the ticker symbol "VECT."

How do I buy shares of VectivBio?

Shares of VECT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VectivBio's stock price today?

One share of VECT stock can currently be purchased for approximately $5.96.

How much money does VectivBio make?

VectivBio (NASDAQ:VECT) has a market capitalization of $202.58 million.

How can I contact VectivBio?

The official website for VectivBio is vectivbio.com. The company can be reached via phone at 41 61 551 30 3 or via email at ir@vectivbio.com.

This page (NASDAQ:VECT) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.